04:38 PM EDT, 03/25/2024 (MT Newswires) -- Aerovate Therapeutics ( AVTE ) reported late Monday a Q4 loss of $0.74 a share, widening from the loss of $0.61 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.71.

The company's cash, cash equivalents and short-term investments were at $122.4 million as of Dec. 31.

The company expects cash, cash equivalents and available-for-sale investments to be enough to fund its operations into 2026.